The following were recorded: vital status, lost to follow-up, transfer out, start on antituberculous treatment.
Person-time of observation were accrued from the initiation on NVP-based ART until either occurrence of death, loss to follow-up, transfer to another ART programme or censoring of observation in July 2007.
Further, these positive findings have supported an assessment of the comparability of ELISpot results from a third central laboratory (UVRI), follow-up transfer of one of the SOPs to a fourth central laboratory (NVITAL), and the implementation of a longitudinal performance monitoring program.
Treatment failures included patients with virological failure, death, lost to follow-up, transfer, withdrawal, or medication switch without viral load support.
CD4 count, HIV RNA viral load, WHO clinical stage at baseline, date of initiation, ART regimen, TB treatment (at ART initiation and subsequently) and outcome (loss to follow-up, transfer out and death) were routinely collected in a database.
Data were collected from patient registers, a hybrid of electronic and paper-based patient management systems, on mortality, loss to follow-up, transfer in and out, functional status and regimen change to second-line treatment.
Outcomes were considered beginning on dialysis day 181 and continuing until patients died, were censored for loss to follow-up (transfer of care, transplant, modality change, withdrawal from dialysis), or until 31 December 2009 (the "outcome period").
